Drug Profile
Pertussis acellular and DTaP vaccine candidates - Novartis Vaccines
Alternative Names: Acellular pertussis combosLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Novartis Vaccines
- Class Bacterial vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diphtheria; Pertussis; Tetanus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Diphtheria(Prevention) in Belgium (IM, Injection)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Pertussis(Prevention) in Belgium (IM, Injection)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Tetanus(Prevention) in Belgium (IM, Injection)